These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12904106)

  • 21. Drug-drug interactions that interfere with statin metabolism.
    Hirota T; Ieiri I
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Jamal SM; Eisenberg MJ; Christopoulos S
    Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin safety: a systematic review.
    Law M; Rudnicka AR
    Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacy clinics. Medication of the month. Cerivastatin (Lipobay, Cholstat)].
    Scheen AJ
    Rev Med Liege; 2000 Feb; 55(2):117-20. PubMed ID: 10769583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
    Maroo BP; Lavie CJ; Milani RV
    Drugs Aging; 2008; 25(8):649-64. PubMed ID: 18665658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.
    Mantel-Teeuwisse AK; Klungel OH; Egberts TC; Verschuren WM; Porsius AJ; de Boer A
    Drug Saf; 2004; 27(1):63-70. PubMed ID: 14720086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.
    Sica DA; Gehr TW
    Curr Opin Nephrol Hypertens; 2002 Mar; 11(2):123-33. PubMed ID: 11856903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current overview of statin-induced myopathy.
    Rosenson RS
    Am J Med; 2004 Mar; 116(6):408-16. PubMed ID: 15006590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rhabdomyolysis and statin therapy: relevance to the elderly.
    Sica DA; Gehr TW
    Am J Geriatr Cardiol; 2002; 11(1):48-55. PubMed ID: 11773716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety issues with statin therapy.
    Talbert RL
    J Am Pharm Assoc (2003); 2006; 46(4):479-88; quiz 488-90. PubMed ID: 16913392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
    Kind AH; Zakowski LJ; McBride PE
    WMJ; 2002; 101(7):53-6. PubMed ID: 12426921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
    Stein EA
    Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.
    Worz CR; Bottorff M
    Expert Opin Pharmacother; 2001 Jul; 2(7):1119-27. PubMed ID: 11583063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statin safety: an assessment using an administrative claims database.
    Cziraky MJ; Willey VJ; McKenney JM; Kamat SA; Fisher MD; Guyton JR; Jacobson TA; Davidson MH
    Am J Cardiol; 2006 Apr; 97(8A):61C-68C. PubMed ID: 16581331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rhabdomyolysis and HMG-CoA reductase inhibitors.
    Omar MA; Wilson JP; Cox TS
    Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
    Ozdemir O; Boran M; Gökçe V; Uzun Y; Koçak B; Korkmaz S
    Angiology; 2000 Aug; 51(8):695-7. PubMed ID: 10959522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.